Is ERAS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on RAS/MAPK is a large, underserved target, with product revenue at ~$0 (no approved products). The bear case rests on erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. Analysts covering it are spread from $18.00 to $30.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $18.00, +3.2% from the $17.45 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

RAS/MAPK is a large, underserved target. RAS mutations drive a meaningful share of lung, pancreatic, and colorectal cancers and have long been considered difficult to drug. The most optimistic analyst target on ERAS is $30.00, +71.9% from the $17.45 price. That figure is only reachable if this thesis works close to its best case.

Erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply. Early Phase 1 response data are preliminary, involve small patient numbers, and may not hold up in larger, controlled studies. The company competes directly with better-financed RAS programs, most notably Revolution Medicines, whose daraxonrasib has shown strong pancreatic-cancer survival data. Ongoing losses mean further dilutive equity raises are likely, and the multi-billion-dollar market cap already assumes substantial clinical and commercial success that is far from guaranteed. The most pessimistic published target is $18.00, +3.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Erasca, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (RAS/MAPK is a large, underserved target) stalling in the reported numbers rather than in the narrative, the risk above (erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Erasca is a clinical-stage precision oncology company developing drugs that target the RAS/MAPK signaling pathway, which drives many lung, pancreatic, and colorectal cancers. Its lead programs are ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, an oral pan-KRAS inhibitor, both in early trials.

No. As a development-stage biotech it has no approved products and essentially no product revenue, and it runs large operating losses. It funds itself with cash on the balance sheet and periodic equity raises rather than sales.

Erasca ended Q1 2026 with roughly $408 million in cash and marketable securities and raised about $550 million more in a July 2026 stock offering. Management projects that funds operations well beyond 2028, though the raises dilute existing shareholders.